Vipul Jairath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vipul Jairath has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Brennan C. Kahan
MRC Clinical Trials Unit, London, United Kingdom
3 shared publications- Brennan C. Kahan
Medical Research Council Centre of Research Excellence in Clinical Trial Innovation in Partnership With NIHR University College London London UK
3 shared publications Kelvin R. Palmer
Western General Hospital, Edinburgh, United Kingdom
3 shared publicationsMichael F. Murphy
NHS Blood and Transplant, Oxford, United Kingdom
3 shared publicationsRichard F.A. Logan
Division of Epidemiology and Public Health and Nottingham Digestive Disease Centre, University of Nottingham, Nottinghamshire, United Kingdom
3 shared publicationsSimon P.L. Travis
Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, United Kingdom
3 shared publications
Latest Publications
- Top Cited Papers
- 1 July 2015
- Published by Elsevier in The Lancet
- Vol. 386 (9989) , 137-144
Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial
- 1 July 2015
- Published by Elsevier in The Lancet
- Vol. 386 (9989) , 137-144
Top Cited PapersRestrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial
- 9 March 2015
- Published by Wiley
- No. 3
Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis
- 9 March 2015
- Published by Wiley
- No. 3
Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis
- Open Access
- 21 November 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-6
Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper gastrointestinal tract confirmed by an internal examination). TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up. Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in the patient’s care, while reducing the potential for bias. When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or method of assessment to reduce the risk of bias. TRIGGER: ISRCTN85757829 . Registered 26 July 2012. TAPPS: ISRCTN47845793 . Registered 28 May 2012.
- 21 November 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-6
Open AccessReducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper gastrointestinal tract confirmed by an internal examination). TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up. Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in the patient’s care, while reducing the potential for bias. When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or method of assessment to reduce the risk of bias. TRIGGER: ISRCTN85757829 . Registered 26 July 2012. TAPPS: ISRCTN47845793 . Registered 28 May 2012.
- Open Access
- 19 November 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-14
HALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial
Gastrointestinal bleeding is a common emergency that causes substantial mortality worldwide. Acute upper and lower gastrointestinal bleeding accounts for about 75,000 hospital admissions each year in the UK and causes the death of about 10% of these patients. Tranexamic acid has been shown to reduce the need for blood transfusion in surgical patients and to reduce mortality in bleeding trauma patients, with no apparent increase in thromboembolic events. A systematic review of clinical trials of upper gastrointestinal bleeding shows a reduction in the risk of death with tranexamic acid but the quality of the trials was poor and the estimates are imprecise. The trials were also too small to assess the effect of tranexamic acid on thromboembolic events. HALT-IT is a pragmatic, randomised, double-blind, placebo-controlled trial which will determine the effect of tranexamic acid on mortality, morbidity (re-bleeding, non-fatal vascular events), blood transfusion, surgical intervention, and health status in patients with acute gastrointestinal bleeding. Eight thousand adult patients who fulfil the eligibility criteria will be randomised to receive tranexamic acid or placebo. Adults with significant acute upper or lower gastrointestinal bleeding can be included if the responsible doctor is substantially uncertain as to whether or not to use tranexamic acid in that particular patient. Trial treatment consists of a loading dose of tranexamic acid (1 g by intravenous injection) or placebo (sodium chloride 0.9%) given as soon as possible after randomisation, followed by an intravenous infusion of 3 g tranexamic acid or placebo (sodium chloride 0.9%) over 24 hours. The main analyses will compare those allocated tranexamic acid with those allocated placebo, on an intention-to-treat basis. Results will be presented as effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses for the primary outcome will be based on time to treatment, source of bleeding (upper versus lower), suspected variceal bleeding and severity of bleeding. A study with 8,000 patients will have over 90% power to detect a 25% reduction in mortality from 10% to 7.5%. Current Controlled Trials ISRCTN11225767 (registration date: 3 July 2012); Clinicaltrials.gov NCT01658124 (registration date: 26 July 2012).
- 19 November 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-14
Open AccessHALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial
Gastrointestinal bleeding is a common emergency that causes substantial mortality worldwide. Acute upper and lower gastrointestinal bleeding accounts for about 75,000 hospital admissions each year in the UK and causes the death of about 10% of these patients. Tranexamic acid has been shown to reduce the need for blood transfusion in surgical patients and to reduce mortality in bleeding trauma patients, with no apparent increase in thromboembolic events. A systematic review of clinical trials of upper gastrointestinal bleeding shows a reduction in the risk of death with tranexamic acid but the quality of the trials was poor and the estimates are imprecise. The trials were also too small to assess the effect of tranexamic acid on thromboembolic events. HALT-IT is a pragmatic, randomised, double-blind, placebo-controlled trial which will determine the effect of tranexamic acid on mortality, morbidity (re-bleeding, non-fatal vascular events), blood transfusion, surgical intervention, and health status in patients with acute gastrointestinal bleeding. Eight thousand adult patients who fulfil the eligibility criteria will be randomised to receive tranexamic acid or placebo. Adults with significant acute upper or lower gastrointestinal bleeding can be included if the responsible doctor is substantially uncertain as to whether or not to use tranexamic acid in that particular patient. Trial treatment consists of a loading dose of tranexamic acid (1 g by intravenous injection) or placebo (sodium chloride 0.9%) given as soon as possible after randomisation, followed by an intravenous infusion of 3 g tranexamic acid or placebo (sodium chloride 0.9%) over 24 hours. The main analyses will compare those allocated tranexamic acid with those allocated placebo, on an intention-to-treat basis. Results will be presented as effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses for the primary outcome will be based on time to treatment, source of bleeding (upper versus lower), suspected variceal bleeding and severity of bleeding. A study with 8,000 patients will have over 90% power to detect a 25% reduction in mortality from 10% to 7.5%. Current Controlled Trials ISRCTN11225767 (registration date: 3 July 2012); Clinicaltrials.gov NCT01658124 (registration date: 26 July 2012).
- 3 September 2014
- Published by Springer Nature
- p. 121-137
Transfusion in Gastrointestinal Bleeding
- 1 May 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (5) , 419-426
Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit
- 1 May 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (5) , 419-426
Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit
- Top Cited PapersOpen Access
- 23 April 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 139
The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies
Adjustment for prognostic covariates can lead to increased power in the analysis of randomized trials. However, adjusted analyses are not often performed in practice.
- 23 April 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 139
Top Cited PapersOpen AccessThe risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies
Adjustment for prognostic covariates can lead to increased power in the analysis of randomized trials. However, adjusted analyses are not often performed in practice.
- Open Access
- 1 February 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (2) , 166-171
Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?
Inflammatory bowel disease (IBD) is a disease-specific risk factor for incident and recurrent venous thromboembolism (VTE). The reasons are acquired, multifactorial, and related to prothrombotic aberrations during active disease, although the mechanisms remain incompletely elucidated. VTE represents a potentially life-threatening extraintestinal manifestation of IBD, but the associated morbidity and mortality can be reduced by appropriate use of thromboprophylaxis. Nevertheless, despite international guidelines advocating thromboprophylaxis in hospitalised patients with IBD, practice is highly variable, since 65% of gastroenterologists may not use pharmacological VTE prophylaxis in hospitalised patients with acute severe colitis. Furthermore, there is no guidance on appropriate prophylaxis for ambulatory outpatients with active disease who are at an appreciable risk of VTE. Thus the question: are we tailoring thromboprophylaxis to those patients with IBD who are most at risk?
- 1 February 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (2) , 166-171
Open AccessThrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?
Inflammatory bowel disease (IBD) is a disease-specific risk factor for incident and recurrent venous thromboembolism (VTE). The reasons are acquired, multifactorial, and related to prothrombotic aberrations during active disease, although the mechanisms remain incompletely elucidated. VTE represents a potentially life-threatening extraintestinal manifestation of IBD, but the associated morbidity and mortality can be reduced by appropriate use of thromboprophylaxis. Nevertheless, despite international guidelines advocating thromboprophylaxis in hospitalised patients with IBD, practice is highly variable, since 65% of gastroenterologists may not use pharmacological VTE prophylaxis in hospitalised patients with acute severe colitis. Furthermore, there is no guidance on appropriate prophylaxis for ambulatory outpatients with active disease who are at an appreciable risk of VTE. Thus the question: are we tailoring thromboprophylaxis to those patients with IBD who are most at risk?
- Open Access
- 22 May 2013
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 27 (3) , 146-153
Restrictive vs Liberal Blood Transfusion for Acute Upper Gastrointestinal Bleeding: Rationale and Protocol for a Cluster Randomized Feasibility Trial
- 22 May 2013
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 27 (3) , 146-153
Open AccessRestrictive vs Liberal Blood Transfusion for Acute Upper Gastrointestinal Bleeding: Rationale and Protocol for a Cluster Randomized Feasibility Trial
- 21 May 2013
- Published by Wiley in Transfusion Medicine
- Vol. 23 (3) , 139-141
Acute upper gastrointestinal bleeding—time for some new triggers?
- 21 May 2013
- Published by Wiley in Transfusion Medicine
- Vol. 23 (3) , 139-141
Acute upper gastrointestinal bleeding—time for some new triggers?